Journal article
EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib
Cancer chemotherapy and pharmacology, Vol.81(5), pp.965-968
05/01/2018
DOI: 10.1007/s00280-018-3571-2
PMID: 29610932
Abstract
EML4-ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4-ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4-ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4-ALK genomic testing may be clinically useful in patients with heavy smoking history.
Details
- Title: Subtitle
- EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib
- Creators
- Thomas Huang - Markey Cancer CenterBrigitte J. Engelmann - University of KentuckyRachael M. Morgan - University of KentuckyKimberly J. Absher - University of KentuckyJill M. Kolesar - University of KentuckyJohn L. Villano - University of Kentucky
- Resource Type
- Journal article
- Publication Details
- Cancer chemotherapy and pharmacology, Vol.81(5), pp.965-968
- Publisher
- Springer Nature
- DOI
- 10.1007/s00280-018-3571-2
- PMID
- 29610932
- ISSN
- 0344-5704
- eISSN
- 1432-0843
- Number of pages
- 4
- Language
- English
- Date published
- 05/01/2018
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696552202771
Metrics
2 Record Views